Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair

BACKGROUND: Despite recent advances in the treatment of multiple myeloma (MM), the prognosis of most patients remains poor, and resistance to traditional and new drugs frequently occurs. EDO-S101 is a novel therapeutic agent conceived as the fusion of a histone deacetylase inhibitor radical to benda...

Descripción completa

Detalles Bibliográficos
Autores principales: López-Iglesias, Ana-Alicia, Herrero, Ana B., Chesi, Marta, San-Segundo, Laura, González-Méndez, Lorena, Hernández-García, Susana, Misiewicz-Krzeminska, Irena, Quwaider, Dalia, Martín-Sánchez, Montserrat, Primo, Daniel, Paíno, Teresa, Bergsagel, P. Leif, Mehrling, Thomas, González-Díaz, Marcos, San-Miguel, Jesús F., Mateos, María-Victoria, Gutiérrez, Norma C., Garayoa, Mercedes, Ocio, Enrique M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477689/
https://www.ncbi.nlm.nih.gov/pubmed/28633670
http://dx.doi.org/10.1186/s13045-017-0495-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477689/
https://www.ncbi.nlm.nih.gov/pubmed/28633670
http://dx.doi.org/10.1186/s13045-017-0495-y

Ejemplares similares